Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Vivar Pomiano, Nancy"'
Autor:
Kharlamova, Nastya, Hermanrud, Christina, Dunn, Nicky, Ryner, Malin, Hambardzumyan, Karen, Vivar Pomiano, Nancy, Marits, Per, Gjertsson, Inger, Saevarsdottir, Saedis, Pullerits, Rille, Fogdell-Hahn, Anna
Publikováno v:
Frontiers in Immunology
Publisher's version (útgefin grein)
A subgroup of patients treated with infliximab lose response to the treatment and one reason for this is the development of anti-drug antibodies (ADA). If used optimally, measuring drug and ADA level could le
A subgroup of patients treated with infliximab lose response to the treatment and one reason for this is the development of anti-drug antibodies (ADA). If used optimally, measuring drug and ADA level could le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::291be7db203b1fd807278d3fd6d2b219
https://hdl.handle.net/20.500.11815/2403
https://hdl.handle.net/20.500.11815/2403
Autor:
Gunnarsson K; specialistläkare i reumatologi, Karolinska universitetssjukhuset, Stockholm., Vivar Pomiano N; med dr, specialistläkare i reumatologi, Karolinska universitetssjukhuset, Stockholm., Tesi B; med dr, ST-läkare i klinisk genetik, Karolinska universitetssjukhuset, Stockholm., Tobiasson M; med dr, överläkare i hematologi, Karolinska universitetssjukhuset, Stockholm., Creignou M; specialistläkare i hematologi, Karolinska universitetssjukhuset, Stockholm., Ungerstedt J; docent, överläkare i hematologi, Karolinska universitetssjukhuset, Stockholm.
Publikováno v:
Lakartidningen [Lakartidningen] 2022 Sep 07; Vol. 119. Date of Electronic Publication: 2022 Sep 07.
Autor:
Kharlamova N; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.; Center for Molecular Medicine, Stockholm, Sweden., Hermanrud C; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.; Center for Molecular Medicine, Stockholm, Sweden., Dunn N; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.; Center for Molecular Medicine, Stockholm, Sweden., Ryner M; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.; Center for Molecular Medicine, Stockholm, Sweden., Hambardzumyan K; Rheumatology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden., Vivar Pomiano N; Rheumatology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden., Marits P; Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden., Gjertsson I; Department of Rheumatology and Inflammation Research, Institution of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Saevarsdottir S; Rheumatology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.; Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland., Pullerits R; Department of Rheumatology and Inflammation Research, Institution of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Department of Clinical Immunology and Transfusion Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden., Fogdell-Hahn A; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.; Center for Molecular Medicine, Stockholm, Sweden.
Publikováno v:
Frontiers in immunology [Front Immunol] 2020 Jul 21; Vol. 11, pp. 1365. Date of Electronic Publication: 2020 Jul 21 (Print Publication: 2020).